ArticleAnnals of hematology2026
Prognostic significance of Ki-67 in grade 3A follicular lymphoma and development of a novel PFS nomogram.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.British journal of haematology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundFollicular lymphoma (FL) is an indolent yet highly heterogeneous B-cell lymphoproliferative disorder. The introduction of CD20 monoclonal antibodies has significantly improved patient survival; however, the optimal therapeutic strategy for grade 3A FL remains controversial. The Ki-67 proliferation index may reflect tumor aggressiveness, but its prognostic and therapeutic implications are not fully established. This study aimed to evaluate the prognostic significance of Ki-67 expression and to develop a predictive model for progression-free survival (PFS) in patients with grade 3A FL.
methodsClinical data from 110 patients with grade 3A FL were retrospectively analyzed. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors for PFS. Kaplan-Meier survival analysis with log-rank tests was used to compare PFS between subgroups stratified by Ki-67 expression and treatment regimen. A nomogram-based predictive model was constructed and validated using the concordance index (C-index), calibration plots, and decision curve analysis (DCA).
resultsHigh Ki-67 expression (≥ 50%) was associated with significantly shorter PFS. Among these patients, those treated with R-CHOP achieved longer PFS than those receiving BR, whereas the opposite trend was observed in patients with low Ki-67 expression (< 50%). High Ki-67 expression combined with CD5 positivity, CD10 negativity, or MUM1 positivity predicted poorer outcomes. Multivariate analysis identified Ki-67, stage, tumor diameter, B symptoms, and β
conclusionGrade 3A FL is characterized by marked clinical and biological heterogeneity. Our findings indicate that Ki-67 expression serves as a valuable prognostic marker that can inform therapeutic decision-making in patients with grade 3A FL. The proposed model integrating Ki-67 and clinical variables enhances PFS prediction and supports individualized treatment strategies for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.